MN33-47 

MN33-47 is a multi-target anti-tumor compound with broad-spectrum anti-proliferative activity. MN33-47 relieves the inhibition of the mitochondrial apoptosis pathway by downregulating the anti-apoptotic protein Bcl-2, while activating caspase-3 and inhibiting Topoisomerase I activity, thereby promoting its degradation through the ubiquitin-proteasome and autophagy-lysosome pathways. MN33-47 can also induce DNA cross-linking and G2/M cell cycle arrest, inhibit cancer cell migration and activate the mitochondrial apoptosis pathway, thus exerting potent anti-tumor effects. MN33-47 can improve the water solubility of SN-38 (HY-13704), and exhibits dose-dependent tumor growth inhibition effects in CT26 tumor-bearing mouse models without obvious toxic and side effects. MN33-47 can be used in related studies on colorectal adenocarcinoma, cervical adenocarcinoma, hepatocellular carcinoma, alveolar basal epithelial adenocarcinoma, gastric cancer and colon cancer^[1].

MN33-47 (0.038-100000 nM; 72 h) potently inhibits the proliferation of HCT-15, HeLa, HepG2, A549, HGC-27, and CT26 cells with IC₅₀=4.77-252.10 nM, showing enhanced activity against HeLa, HepG2, and CT26 cells relative to control treatments^[1].
MN33-47 (100 nM; 24, 48 h) significantly inhibits the migration of CT26 cells at 24 h and 48 h, showing greater efficacy than single-agent chlormethine hydrochloride (HY-B1253) (CH) or SN-38 (HY-13704)^[1].
MN33-47 (100 nM; 48 h) induces G2/M phase arrest in 46.3% of CT26 cells after 48 h, showing stronger cell cycle blockade than CH, SN-38, or their physical mixture^[1].
MN33-47 (100 nM; 48 h) induces apoptosis in 50.63% of CT26 cells after 48 h, exhibiting significantly greater pro-apoptotic efficacy than CH, SN-38, or their physical mixture^[1].
MN33-47 (1-10000 nM, 1 μM; 72 h) dose-dependently reduces Topo I protein levels in CT26 cells via the ubiquitin-proteasome and autophagy-lysosome pathways, and at 1 μM, it more effectively downregulates Bcl-2 and activates caspase-3 than SN-38, CH, or their physical mixture^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MN33-47 (1.56-6.24 mg/kg; i.p.; daily; 10 days) exhibits dose-dependent, potent antitumor activity in CT26 tumor-bearing BALB/c mice, achieving a 75.73% tumor inhibition rate at the high dose of 6.24 mg/kg, with no observable systemic toxicity or organ damage^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

596.89

C₂₇H₂₈Cl₃N₃O₆

CCC1=C2C(C(N3C2)=CC([C@@](O)(CC)C(OC4)=O)=C4C3=O)=NC5=CC=C(OC(N(CCCl)CCCl)=O)C=C51.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang X, et al. Salt form and phosphate modification of an SN-38-nitrogen mustard conjugate: Overcoming water solubility limitations, combined efficacy, and broadened antitumor Spectrum. Bioorg Chem. 2026;175:109765.